These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34024024)

  • 21. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
    Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
    Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
    J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis.
    Zampino S; Sheikh FH; Vaishnav J; Judge D; Pan B; Daniel A; Brown E; Ebenezer G; Polydefkis M
    Neurology; 2023 May; 100(19):e2036-e2044. PubMed ID: 36941075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
    Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
    Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
    Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
    ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS).
    Cruz MW; Pinto MV; Pinto LF; Gervais R; Dias M; Perez C; Mundayat R; Ong ML; Pedrosa RC; Foguel D
    Arq Neuropsiquiatr; 2019 Feb; 77(2):96-100. PubMed ID: 30810593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis.
    Okada M; Misumi Y; Masuda T; Takashio S; Tasaki M; Matsushita H; Ueda A; Inoue Y; Nomura T; Nakajima M; Yamashita T; Shinriki S; Matsui H; Tsujita K; Ando Y; Ueda M
    ESC Heart Fail; 2021 Apr; 8(2):1178-1185. PubMed ID: 33381924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptomatic Val122del mutated hereditary transthyretin amyloidosis: Need for early diagnosis and prioritization for heart and liver transplantation.
    Schettini AV; Llado L; Heimbach JK; Costello JG; Tranäng M; Van Caenegem O; Daly RC; Van den Bergh P; Casanovas C; Fabregat J; Poterucha JJ; Foguenne M; Ericzon BG; Lerut J
    Hepatobiliary Pancreat Dis Int; 2021 Aug; 20(4):323-329. PubMed ID: 34116942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Garcia-Pavia P; Kristen AV; Drachman B; Carlsson M; Amass L; Angeli FS; Maurer MS;
    J Card Fail; 2024 Jun; ():. PubMed ID: 38909877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis.
    Alves-Ferreira M; Azevedo A; Coelho T; Santos D; Sequeiros J; Alonso I; Sousa A; Lemos C
    Amyloid; 2021 Jun; 28(2):100-106. PubMed ID: 33461327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Mundayat R; Stewart M; Alvir J; Short S; Ong ML; Keohane D; Rill D; Sultan MB
    Neurol Ther; 2018 Jun; 7(1):87-101. PubMed ID: 29633228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
    Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
    Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of
    Guo H; Wu S; Xiang X; Wang S; Fang Z; Ye Q; Zou Y; Wang Y; Peng D; Ma X
    Ann Nucl Med; 2024 Apr; 38(4):288-295. PubMed ID: 38252229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.
    Yarlas A; Lovley A; McCausland K; Brown D; Vera-Llonch M; Conceição I; Karam C; Khella S; Obici L; Waddington-Cruz M
    Neurol Ther; 2021 Dec; 10(2):865-886. PubMed ID: 34355354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropathic pain experience in symptomatic and presymptomatic subjects carrying a transthyretin gene mutation.
    Tozza S; Luigetti M; Antonini G; Mazzeo A; Severi D; Di Paolantonio A; Leonardi L; Russo M; Romano A; Forcina F; Gentile L; Nolano M; Mattia C; Manganelli F
    Front Neurol; 2023; 14():1109782. PubMed ID: 36846120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: a Single-Centre Experience.
    Luigetti M; Tortora A; Romano A; Di Paolantonio A; Guglielmino V; Bisogni G; Gasbarrini A; Calabresi P; Sabatelli M
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):339-343. PubMed ID: 32919418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area.
    Wang S; Sun J; Lu Q; Li H; Zhang Y
    Int Med Case Rep J; 2022; 15():299-306. PubMed ID: 35734096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis.
    Yamaguchi H; Kawahara H; Kodera N; Kumaki A; Tada Y; Tang Z; Sakai K; Ono K; Yamada M; Hanayama R
    Front Mol Biosci; 2022; 9():839917. PubMed ID: 35402512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between hearing loss and hereditary ATTR amyloidosis.
    Bartier S; Bodez D; Kharoubi M; Guellich A; Canouï-Poitrine F; Chatelin V; Coste A; Damy T; Béquignon E
    Amyloid; 2019 Dec; 26(4):234-242. PubMed ID: 31502881
    [No Abstract]   [Full Text] [Related]  

  • 40. Hereditary transthyretin amyloidosis with hydrocephalus at 27 years old: A case report.
    Kamimoto H; Tomioka D; Hanato K; Takagi S; Uemura Y; Dochi K; Sakai H; Ueno Y
    J Cardiol Cases; 2024 May; 29(5):201-204. PubMed ID: 39100516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.